An interview with Abidemi from at the Wyss Institute.
Moderna’s ‘year of transition’: Changing gears from Covid-19 to RSV as vaccine approval date looms
Wrapping what it calls a “year of transition,” Moderna is further expanding its commercial operations toward the potential launch of its RSV vaccine while downsizing